How Interferon Signals May Weaken Beta Cells' Immune Defense

Beta cells, which produce insulin, face a difficult situation in Type 1 diabetes: the immune system mistakes them for a threat and attacks them. To defend themselves, beta cells produce a protein called PD-L1 (programmed death ligand 1). This protein acts as a molecular 'brake,' sending signals to immune cells—particularly CD8+ T cells—to stand down and stop attacking.

Beta cells deploy PD-L1 in two ways: some remains anchored to the cell surface, while other copies travel inside tiny bubble-like structures called extracellular vesicles, which float away from the cell to communicate with distant immune cells. Both strategies help protect beta cells from destruction.

Interferon is a chemical messenger that cells release during viral infections or inflammation. When interferon signals reach beta cells, something unexpected happens: the cells begin making an altered form of PD-L1, called PD-L1Δ3, that lacks a critical section of the protein.

This altered version never reaches the cell surface. Instead, it gets trapped inside the cell, where it cannot interact with immune cells. Worse, the faulty protein cannot bind to PD-1, the 'receiver' on immune cells that would normally receive the protective signal.

Because PD-L1Δ3 is stuck inside the cell, it also cannot be packaged into the protective vesicles that would carry it away to reach distant immune cells. The result: beta cells lose a crucial layer of defense at a time when interferon signals suggest danger is present.

Researchers discovered that some families with neonatal Type 1 diabetes—onset in infants—carry a rare genetic change in the gene that makes PD-L1. This mutation causes the body to naturally produce a protein with the same defect as PD-L1Δ3: it remains trapped inside beta cells and cannot protect them.

This genetic finding suggests that impaired PD-L1 function is not just a side effect of inflammation, but may be a genuine risk factor for Type 1 diabetes. When beta cells cannot produce functioning PD-L1, they become more vulnerable to immune attack.

This research reveals a previously unknown pathway linking viral infections or inflammation to beta cell destruction in Type 1 diabetes. The discovery that interferon triggers production of a non-functional PD-L1 protein suggests the immune system has found a way to exploit a moment of inflammation to attack beta cells more effectively.

Understanding this mechanism could eventually lead to new approaches to protect beta cells—whether by stabilizing the functional form of PD-L1, blocking the production of the faulty version, or finding ways to reinforce beta cell defenses during viral infections. However, much work remains to confirm these findings in human disease and to develop safe, effective treatments based on them.

Source: bioRxiv : the preprint server for biology. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.